Satterlee Stephens Represents Y-mAbs Therapeutics, Inc. in $50 Million Private Placement of Common Stock


Dwight A. Kinsey, Michael D. Baird, Rina Patel and Michael J. Kearney represented Satterlee Stephens’ client, Y-mAbs Therapeutics, Inc., in its recent $50 million private placement of common stock which closed on October 13, 2017.  Y-mAbs is a late-stage clinical biopharmaceutical company focused on developing novel antibody-based treatments for patients with cancer. The firm has represented Y-mAbs in other matters since its inception in April 2015, including its earlier funding rounds totaling approximately $40 million.